Íîâîñòè
õèðóðãèè

 Æóðíàë âêëþ÷åí
â ñèñòåìó öèòèðîâàíèÿ Scopus
journal cover
android icon Ïðèëîæåíèå Android

2007 ã. ¹3 Òîì 15

ÎÐÈÃÈHÀËÜHÛÅ ÈÑÑËÅÄÎÂÀHÈß

À.Â. ÃÈÄÐÀHÎÂÈ×

ÀÓÒÎÊÐÈHHÛÉ ÔÀÊÒÎÐ ÏÎÄÂÈÆHÎÑÒÈ ÊËÅÒÎÊ Â ÑÛÂÎÐÎÒÊÅ ÊÐÎÂÈ ÁÎËÜHÛÕ ÐÀÊÎÌ ÌÎËÎ×HÎÉ ÆÅËÅÇÛ.

ÓÎ «Âèòåáñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò»,
Ðåñïóáëèêà Áåëàðóñü

 äàííîé ñòàòüå ïðîâåäåí àíàëèç àêòèâíîñòè àóòîêðèííîãî ôàêòîðà ïîäâèæíîñòè (AMF) â ñûâîðîòêå êðîâè çäîðîâûõ äîíîðîâ è áîëüíûõ ðàêîì ìîëî÷íîé æåëåçû íà ðàçëè÷íûõ ñòàäèÿõ çàáîëåâàíèÿ. Óñòàíîâëåíî ñòàòèñòè÷åñêè çíà÷èìîå óâåëè÷åíèå àêòèâíîñòè AMF â ñûâîðîòêå êðîâè áîëüíûõ ðàêîì ìîëî÷íîé æåëåçû ïî ñðàâíåíèþ ñ äîíîðàìè. Ó áîëüíûõ ñ ìåòàñòàòè÷åñêèì ðàêîì ìîëî÷íîé æåëåçû àêòèâíîñòü AMF ìàêñèìàëüíà. Îòìå÷åí ñòàáèëüíûé ïîâûøåííûé óðîâåíü àêòèâíîñòè AMF â 1-îé, 2-îé, 3-åé ñòàäèÿõ ðàêà ìîëî÷íîé æåëåçû, â 4-îé ñòàäèè ðàêà ìîëî÷íîé æåëåçû àêòèâíîñòü AMF çíà÷èòåëüíî óâåëè÷åíà. Çíà÷èòåëüíîå óâåëè÷åíèå àêòèâíîñòè AMF â ñûâîðîòêå êðîâè áîëüíûõ ðàêîì ìîëî÷íîé æåëåçû ìîæåò áûòü ñêðèíèãîâûì ìàðêåðîì ðèñêà ðàííåãî ãåìàòîãåííîãî ìåòàñòàçèðîâàíèÿ.

Êëþ÷åâûå ñëîâà: ðàê ìîëî÷íîé æåëåçû, àóòîêðèííûé ôàêòîð ïîäâèæíîñòè, AMF.
ñ. 8 - 15 îðèãèíàëüíîãî èçäàíèÿ
Ñïèñîê ëèòåðàòóðû
  1. Purification of B16-F1 melanoma autocrine motility factor and its receptor / S. Silletti [et al.] // Cancer Res. – 1991. – Vol. 51. – P. 3507–3511.
  2. Tsuboi, K. K. Phosphoglucose isomerase from human erythrocyte. Preparation and properties / K. K. Tsuboi, K. Fukunaga, C. H. Chervenka // J. Biol. Chem.– 1971.– Vol. 246, N 24.– P. 7586–7594.
  3. Neuroleukin: a lymphokine product of lectin-stimulated T cells / M. E. Gurney [et al.] // Science. – 1986. – Vol. 234. – P. 574–581.
  4. The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase / W. Xu [et al.] // Blood. – 1996. – Vol. 87. – P. 4502–4506.
  5. Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA) / E. Beutler [et al.] // Blood Cells Mol. Dis. – 1997. – Vol. 23. – P. 402–409.
  6. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme / I. Matsumoto [et al.] // Science. – 1999. – Vol. 286. – P. 1732–1735.
  7. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer / Y. Hirono [et al.] // Br. J. Cancer. – 1996. – Vol. 74. – P. 2003–2007.
  8. Autocrine motility factor receptor in human bladder carcinoma: gene expression, loss of cell-contact regulation and chromosomal mapping / S. Silletti [et al.] // Int. J. Oncol. – 1993. – ¹ 3. – P. 801–807.
  9. Autocrine motility factor signaling induces tumour apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression /A. Haga [et al.] // Int. J. Cancer. – 2003. – Vol. 107. – P. 707–714.
  10. Activation of small GTPase Rho is required for autocrine motility factor signaling / S. Tsutsumi [et al.] // Cancer Res. – 2002. – Vol. 62. – P. 4484–4490.
  11. Tumour autocrine motility factor responses are mediated through cell contact and focal adhesion rearrangement in the absence of new tyrosine phosphorylation in metastatic cells / S. Silletti [et al.] // Am. J. Pathol. – 1996. – Vol. 148. – P. 1649–1660.
  12. Autocrine motility factor signaling enhances pancreatic cancer metastasis / S. Tsutsumi [et al.] // Clin. Cancer. Res.– 2004.– N 10.–P. 7775–7784.
  13. Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants / S. Silletti [et al.] // Cancer Res. – 1994. – Vol. 54. – P. 5752–5756.
  14. Regulation of tumor cell motility by 12(S)-HETE / S. Silletti [et al.] // Adv. Exp. Med. Biol. – 1997. – Vol. 400B.– P. 683–692.
  15. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems / J. Timar [et al.] // Clin. Exp. Metastasis. – 2002. – Vol. 19. – P. 225–232.
  16. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins / T. Torimura [et al.] // Hepatology. – 2001. – Vol. 34. – P. 62–71.
  17. Autocrine motility factor signaling enhances pancreatic cancer metastasis / S. Tsutsumi [et al.] // Clin. Cancer Res. – 2004. – N 10. – P. 7775-7784.
  18. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer / Y. Hirono [et al.] // Br. J. Cancer. – 1996. – Vol. 74. – P. 2003–2007.
  19. Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer / I. Takanami [et al.] // Int. J.Cancer. – 2001. – Vol. 95. – P. 384–387.
  20. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems / J. Timar [et al.] // Clin. Exp. Metastasis. – 2002. – Vol. 19. – P. 225–232
  21. Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer / I. Takanami [et al.] // Int. J. Cancer. – 2001. – Vol. 95. – P. 384–387.
  22. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumour effects of AMF inhibitors / A. H. Talukder [et al.] // Clin. Cancer Res. – 2002. – N 8. – P. 3285-3289.
  23. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer / A. Ristimaki [et al.] // Cancer Res. – 2002. – Vol. 62. – P. 632-635.
  24. Semenza, G. L. Targeting HIF-1 for cancer therapy / G. L. Semenza // Nat. Rev. Cancer. – 2003. – N 3. – P. 721-732.
  25. Regulation of the hypoxia-inducible transcription factor 1á by the ubiquitine-proteosome pathway / P. J. Kallio // J. Biol. Chem. – 1999. – Vol. 247. – P. 6519–6525.
  26. Semenza, G. L. Regulation of mammalian homeostasis by hypoxia-inducible factor / G. L. Semenza // Annu. Rev. Cell Dev. Biol. – 1999. – Vol. 15. – P. 551–578.
  27. Êëèíè÷åñêàÿ ôåðìåíòîëîãèÿ / ïîä ðåä. Ý. Ùåêëèêà // Ïîëüñêîå ãîñóäàðñòâåííîå ìåäèöèíñêîå èçäàòåëüñòâî. – Âàðøàâà, 1966. – 491 ñ.
Àäðåñ äëÿ êîððåñïîíäåíöèè:
210023, Ðåñïóáëèêà Áåëàðóñü, ã. Âèòåáñê, ïð-ò. Ôðóíçå, 27
e-mail: admin@vgmu.vitebsk.by
Êîíòàêòû | ©Âèòåáñêèé ãîñóäàðñòâåííûé ìåäèöèíñêèé óíèâåðñèòåò, 2007-2023